Denmark· DK-28105219513
Lyxumia
A lixisenatide product containing lixisenatid, registered in Denmark by Sanofi Winthrop Industrie. The same ATC class is registered in 5 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Lixisenatide is registered in 5 of 19 countries.
Countries holding a registration under ATC A10BJ03 (lixisenatide), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 3 of them publish a price we can compare per daily dose
Lixisenatide · ATC A10BJ03
5 / 19 countries
- Belgiumprice
- Denmark
- Finlandprice
- Polandprice
- United Kingdom
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- lixisenatid
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Denmark (DK)
- ATC code
- A10BJ03
- ATC class
- Lixisenatide
- Defined daily dose
- 20 mcg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28105219513
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
304 interactions on record for lixisenatide.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lixisenatide · interactions on record
304 records
- 3 severe
- 259 moderate
- 42 minor
Most severe, free to view
- GatifloxacinJ01MA16severe
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A10BJ03
Lixisenatide, as other registers publish it.
- PolandLyxumiaSanofi Winthrop Industrie
- DenmarkLyxumiaSanofi Winthrop Industrie
- PolandLyxumiaSanofi Winthrop Industrie
- PolandLyxumiaSanofi Winthrop Industrie
- DenmarkLyxumiaSanofi Winthrop Industrie
- FinlandLyxumiaSanofi Winthrop Industrie
- FinlandLyxumiaSanofi Winthrop Industrie
- BelgiumLyxumia 10 µgSanofi-Aventis Groupe
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e9ce0399-f50e-4f50-b678-175413d6caa0 GET /v1/drugs/e9ce0399-f50e-4f50-b678-175413d6caa0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "injektionsvæske, opløsning i fyldt pen",
"source": "dkma",
"strength": "10 + 20 mikrg",
"auth_role": "MOD",
"dk_drugid": "28105219513",
"substance": "lixisenatid",
"auth_procedure": "Central",
"in_medicinpriser": false,
"registration_date_serial": "41306"
}See everything about lixisenatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.